Study analysis · Proceedings of the National Academy of Sciences · 2016
A 'longevity hormone' boosted 50–100× in mice kept their thymus young—but the human absolute benefit is still a black box.
In mice, extra FGF21 protected the thymus from aging and helped immune recovery after radiation, but we don't yet know if it does the same in people.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done in mice, not people. It shows that a hormone called FGF21 helps keep the mouse thymus young and may protect the immune system as mice age. But we don't know if it works the same way in humans, so we can't say it will prevent aging in people.
What’s the bottom line?
In mice, FGF21—a hormone linked to fasting and longevity—helps protect the thymus, the organ that makes T cells, from shrinking with age. Note: corrections/errata were published; check the notices for updated information.
How strong is this study?
The scientists used mice that were genetically modified to make more or less FGF21 and compared them to normal mice. That's a good way to test cause and effect in animals, but because it's not in humans, we need more research to know if it applies to us.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a preclinical animal study using genetic gain- and loss-of-function in mice. While it can demonstrate cause-effect relationships within the mouse model, it cannot establish causation in humans. Species differences in immune system biology, thymic aging, and FGF21 signaling mean that human causal claims are not supported. The Oxford CEBM hierarchy is designed for human clinical evidence; animal studies fall outside it and provide only mechanistic hypotheses.
No Conflicts
No conflicts of interest identified
No conflicts identified.
The provided excerpt does not include an acknowledgements, funding, or conflict of interest section. Authors are affiliated with Yale University, UT Southwestern Medical Center, and Howard Hughes Medical Institute; no industry affiliations are listed.
Key takeaways
- 01
In mice, FGF21 overexpression meant 50–100 times higher circulating FGF21 than normal mice and preserved thymic size/cellularity at 14 months; FGF21 loss in middle age accelerated thymic aging and increased death after irradiation/HSCT.
- 02
No human absolute risk or benefit was reported.
- 03
This was a mouse study, so it does not give a human absolute risk or absolute benefit.
- 04
It suggests FGF21 may help maintain thymic T-cell production in mice; the human absolute effect was not reported in this study.
Surprising findings
- The thymus makes more FGF21 than the liver, the classic source of circulating FGF21.FGF21 is known as a liver-derived metabolic hormone, so high thymic expression was unexpected.
- Aged mouse thymuses contain spiculate crystals inside macrophages that resemble Charcot–Leyden crystals.Such crystals rarely form spontaneously in mammalian tissues and are usually linked to allergic or parasitic inflammation.
- Young FGF21-knockout mice have normal thymic development; problems only emerge in middle age.It suggests FGF21 is not required for building the thymus but is important for maintaining it during aging.
Practical takeaways
Don't try to boost FGF21 for immune aging based on this study alone.
Mouse study; no human dosing, safety, or absolute risk/benefit data. Corrections exist.
low confidenceIf interested in caloric restriction for immune health, treat mouse FGF21 findings as hypothesis-generating, not proof.
Human CR may have risks, and the study only measured thymic FGF21 in mice.
low confidenceFor HSCT patients, ask about clinical trials targeting thymic regeneration rather than self-experimentation.
The lethality and reconstitution data are from mice, not humans.
low confidenceWhen sharing this study, always label effect sizes as relative (e.g., 50–100× higher FGF21) and note species.
No human absolute risk was reported, so absolute framing is not derivable.
high confidenceWhy this study matters
FGF21: The Thymus's Fountain of Youth?
In mice, thymic FGF21 declines with age, but 40% caloric restriction kept it higher. Genetic overexpression causing 50–100× higher circulating FGF21 relative to wild-type preserved thymic size and cellularity at 14 months, increased naive T cells, and reduced effector memory T cells. No human absolute risk or benefit was reported.
The thymus shrinks with age, which weakens immune responses to new infections and vaccines. If FGF21 could slow that in humans, it might extend immune healthspan.
Knockout Mice Fall Apart After Radiation
Middle-aged mice lacking FGF21 showed accelerated thymic aging, increased lethality after lethal irradiation and hematopoietic stem cell transplantation (HSCT), and delayed T-cell reconstitution. The study did not report human absolute risk.
HSCT and chemotherapy patients often suffer from poor immune recovery. Targeting the FGF21 pathway might one day improve transplant outcomes.
It's Not Just Fat—FGF21 Reduces Thymic Lipotoxicity
FGF21 overexpression reduced intrathymic lipid, increased perithymic brown adipose tissue, and reduced crystal-laden macrophages in aged mice. The crystals resembled Charcot–Leyden crystals, which are linked to inflammation.
The aging thymus fills with fat and inflammatory debris. FGF21 seems to help burn that fat locally and reduce damage.
Direct Signaling in Thymic Stromal Cells
FGF21 and its coreceptor βKlotho are coexpressed in thymic epithelial cells and postcapillary venules. Treating thymic stromal cells with FGF21 induced ERK phosphorylation, suggesting direct local signaling rather than only systemic metabolic effects.
This shows FGF21 isn't just a liver hormone—it acts directly on the immune organ's support cells.
Mouse-Only Warning: Hype Check
The study is mouse mechanistic data with published corrections/errata, no randomization or blinding described, and no effect sizes or confidence intervals. Human absolute risk/benefit was not reported.
It's a reminder that promising mouse findings often fail to translate, and corrections mean readers should check the notices.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In mice, FGF21—a hormone linked to fasting and longevity—helps protect the thymus, the organ that makes T cells, from shrinking with age. Note: corrections/errata were published; check the notices for updated information.
Research results
In mice, FGF21 overexpression meant 50–100 times higher circulating FGF21 than normal mice and preserved thymic size/cellularity at 14 months; FGF21 loss in middle age accelerated thymic aging and increased death after irradiation/HSCT. No human absolute risk or benefit was reported.
What this means - more context
This was a mouse study, so it does not give a human absolute risk or absolute benefit. It suggests FGF21 may help maintain thymic T-cell production in mice; the human absolute effect was not reported in this study.
To determine whether FGF21 regulates age-related thymic involution and T-cell senescence in mice.
In mice, thymic FGF21 declines with age and is induced by caloric restriction. FGF21 overexpression protected against age-related thymic involution and increased naïve T cells, while FGF21 loss accelerated thymic aging and impaired recovery after irradiation/HSCT. NOTE: This study has published corrections/errata; readers should check the correction notices for updated information. Findings are mouse mechanistic data; human absolute risk was not reported.
Methods Used
Male/female C57BL/6 mice including WT, Fgf21 transgenic, and Fgf21−/−; ages 1–26 months; 40% caloric restriction; flow cytometry, qPCR, histology, electron microscopy, irradiation/HSCT, sjTREC, and TCR spectratyping.
Main Finding
In mice, FGF21 expression declines with age and is induced by caloric restriction; FGF21 overexpression (50–100 times higher circulating FGF21 relative to WT) protected against age-related thymic involution, increased cortical thymic epithelial cells and earliest thymocyte progenitors, reduced intrathymic lipid, and increased naïve T cells, while FGF21 loss accelerated thymic aging and increased lethality after irradiation/HSCT. These are mouse mechanistic findings; no human relative risk or absolute risk estimates were reported.
Confidence Level
Moderate; genetic gain/loss-of-function in mice with multiple ages and independent cohorts, but no randomization/blinding reported, no effect sizes or confidence intervals reported, and corrections/errata exist.
Study Flags
Red Flags
- •Published correction/erratum; check notices
- •Animal-only mechanistic study; human absolute risk/benefit not reported
- •No effect sizes or confidence intervals; randomization/blinding not described
Surprising Findings
The thymus makes more FGF21 than the liver, the classic source of circulating FGF21.
FGF21 is known as a liver-derived metabolic hormone, so high thymic expression was unexpected.
Practical Takeaways
Don't try to boost FGF21 for immune aging based on this study alone.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study was done in mice, not people. It shows that a hormone called FGF21 helps keep the mouse thymus young and may protect the immune system as mice age. But we don't know if it works the same way in humans, so we can't say it will prevent aging in people.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Controlled genetic gain-of-function (Fgf21 transgenic) and loss-of-function (Fgf21 knockout) models
- Multiple age cohorts (young, middle-aged, old) to assess aging effects
- Independent replication in two separate animal facilities
Weaknesses
- Animal model limits direct translation to humans
- Randomization and blinding are not reported, raising risk of performance and detection bias
- Sample sizes are not consistently reported, and some analyses may be underpowered
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In mice, FGF21—a hormone linked to fasting and longevity—helps protect the thymus, the organ that makes T cells, from shrinking with age. Note: corrections/errata were published; check the notices for updated information.
Research results
In mice, FGF21 overexpression meant 50–100 times higher circulating FGF21 than normal mice and preserved thymic size/cellularity at 14 months; FGF21 loss in middle age accelerated thymic aging and increased death after irradiation/HSCT. No human absolute risk or benefit was reported.
What this means - more context
This was a mouse study, so it does not give a human absolute risk or absolute benefit. It suggests FGF21 may help maintain thymic T-cell production in mice; the human absolute effect was not reported in this study.
To determine whether FGF21 regulates age-related thymic involution and T-cell senescence in mice.
In mice, thymic FGF21 declines with age and is induced by caloric restriction. FGF21 overexpression protected against age-related thymic involution and increased naïve T cells, while FGF21 loss accelerated thymic aging and impaired recovery after irradiation/HSCT. NOTE: This study has published corrections/errata; readers should check the correction notices for updated information. Findings are mouse mechanistic data; human absolute risk was not reported.
Methods Used
Male/female C57BL/6 mice including WT, Fgf21 transgenic, and Fgf21−/−; ages 1–26 months; 40% caloric restriction; flow cytometry, qPCR, histology, electron microscopy, irradiation/HSCT, sjTREC, and TCR spectratyping.
Main Finding
In mice, FGF21 expression declines with age and is induced by caloric restriction; FGF21 overexpression (50–100 times higher circulating FGF21 relative to WT) protected against age-related thymic involution, increased cortical thymic epithelial cells and earliest thymocyte progenitors, reduced intrathymic lipid, and increased naïve T cells, while FGF21 loss accelerated thymic aging and increased lethality after irradiation/HSCT. These are mouse mechanistic findings; no human relative risk or absolute risk estimates were reported.
Confidence Level
Moderate; genetic gain/loss-of-function in mice with multiple ages and independent cohorts, but no randomization/blinding reported, no effect sizes or confidence intervals reported, and corrections/errata exist.
Study Flags
Red Flags
- •Published correction/erratum; check notices
- •Animal-only mechanistic study; human absolute risk/benefit not reported
- •No effect sizes or confidence intervals; randomization/blinding not described
Surprising Findings
The thymus makes more FGF21 than the liver, the classic source of circulating FGF21.
FGF21 is known as a liver-derived metabolic hormone, so high thymic expression was unexpected.
Practical Takeaways
Don't try to boost FGF21 for immune aging based on this study alone.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study was done in mice, not people. It shows that a hormone called FGF21 helps keep the mouse thymus young and may protect the immune system as mice age. But we don't know if it works the same way in humans, so we can't say it will prevent aging in people.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Controlled genetic gain-of-function (Fgf21 transgenic) and loss-of-function (Fgf21 knockout) models
- Multiple age cohorts (young, middle-aged, old) to assess aging effects
- Independent replication in two separate animal facilities
Weaknesses
- Animal model limits direct translation to humans
- Randomization and blinding are not reported, raising risk of performance and detection bias
- Sample sizes are not consistently reported, and some analyses may be underpowered
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists used mice that were genetically modified to make more or less FGF21 and compared them to normal mice. That's a good way to test cause and effect in animals, but because it's not in humans, we need more research to know if it applies to us.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 513 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a preclinical animal study using genetic gain- and loss-of-function in mice. While it can demonstrate cause-effect relationships within the mouse model, it cannot establish causation in humans. Species differences in immune system biology, thymic aging, and FGF21 signaling mean that human causal claims are not supported. The Oxford CEBM hierarchy is designed for human clinical evidence; animal studies fall outside it and provide only mechanistic hypotheses.
No Conflicts
No conflicts of interest identified
No conflicts identified.
The provided excerpt does not include an acknowledgements, funding, or conflict of interest section. Authors are affiliated with Yale University, UT Southwestern Medical Center, and Howard Hughes Medical Institute; no industry affiliations are listed.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Siim Land cite this study, drawing 1 claim from it.
- Correlational evidence
The evidence shows a real association, but the studies are observational, so they cannot prove cause and effect. Stronger studies could still change the picture.
Evidence
Authored by
5 researchersIf this is your work, this is how we attribute it on Fit Body Science. Yun‐Hee Youm is listed as the lead author.